Adjuvant concurrent chemoradiation for node-positive adenocarcinoma of the duodenum.
Arch Surg., Mar;142(3):285-8 (2007)
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.
Cancer Chemother. Pharmacol., Mar;61(3):423-33 (2008)
Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma.
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., Sep;856(1-2):198-204 (2007)
Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies.
Ann. Oncol., Feb;19(2):374-9 (2008)
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
J. Clin. Oncol., Dec;26(34):5504-10 (2008)
Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors.
J. Clin. Oncol., Sep;26(25):4172-9 (2008)
A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer.
Transl Oncol., 3(6):373-9 (2010)
A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma.
Cancer Chemother. Pharmacol., Feb;69(2):415-24 (2012)
Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer.
Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.
Clin. Cancer Res., Aug;7(8):2330-9 (2001)
A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule.
Clin. Cancer Res., Oct;7(10):3047-55 (2001)
Evolving therapies: farnesyltransferase inhibitors.
Curr Oncol Rep., Jan;4(1):29-36 (2002)
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.
J. Natl. Cancer Inst., Dec;94(24):1883-8 (2002)
A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors.
Clin. Cancer Res., Jan;11(2 Pt 1):664-71 (2005)
Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours.
Eur. J. Cancer., Jan;43(1):78-86 (2007)
Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data.
Cancer Chemother. Pharmacol., 33(6):493-6 (1994)
Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer.
Drug Metab. Dispos., 20(5):706-13 (1992)
Clinical toxicities encountered with paclitaxel (Taxol).
Semin. Oncol., Aug;20(4 Suppl 3):1-15 (1993)
Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting.
J. Clin. Oncol., Oct;11(10):2010-20 (1993)
Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies.
Ann. Neurol., Mar;35(3):304-11 (1994)